Hoth Therapeutics (HOTH) Competitors $1.28 -0.01 (-0.78%) Closing price 04:00 PM EasternExtended Trading$1.28 0.00 (0.00%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH vs. CUE, ZIVO, IZTC, APLT, ICCC, IMA, VRCA, DRRX, BMEA, and ANLShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Cue Biopharma (CUE), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), Applied Therapeutics (APLT), ImmuCell (ICCC), ImageneBio (IMA), Verrica Pharmaceuticals (VRCA), DURECT (DRRX), Biomea Fusion (BMEA), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Its Competitors Cue Biopharma ZIVO Bioscience Invizyne Technologies Applied Therapeutics ImmuCell ImageneBio Verrica Pharmaceuticals DURECT Biomea Fusion Adlai Nortye Hoth Therapeutics (NASDAQ:HOTH) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Does the media refer more to HOTH or CUE? In the previous week, Cue Biopharma had 4 more articles in the media than Hoth Therapeutics. MarketBeat recorded 8 mentions for Cue Biopharma and 4 mentions for Hoth Therapeutics. Hoth Therapeutics' average media sentiment score of 1.47 beat Cue Biopharma's score of 0.22 indicating that Hoth Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hoth Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer HOTH or CUE? Hoth Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 212.50%. Cue Biopharma has a consensus price target of $4.00, suggesting a potential upside of 384.26%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, HOTH or CUE? Hoth Therapeutics has higher earnings, but lower revenue than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Hoth Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$8.19M-$1.07-1.20Cue Biopharma$9.29M6.83-$40.67M-$0.67-1.23 Is HOTH or CUE more profitable? Hoth Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -469.35%. Hoth Therapeutics' return on equity of -114.32% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -114.32% -105.92% Cue Biopharma -469.35%-230.13%-111.16% Do institutionals and insiders have more ownership in HOTH or CUE? 7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 6.9% of Hoth Therapeutics shares are held by company insiders. Comparatively, 10.8% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, HOTH or CUE? Hoth Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. SummaryHoth Therapeutics beats Cue Biopharma on 9 of the 16 factors compared between the two stocks. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.97M$3.13B$5.69B$9.80BDividend YieldN/A2.23%4.59%4.07%P/E Ratio-1.2020.7930.6825.54Price / SalesN/A371.51464.67116.55Price / CashN/A43.0338.2159.48Price / Book1.758.638.996.13Net Income-$8.19M-$54.65M$3.25B$264.89M7 Day Performance7.56%6.59%4.75%2.66%1 Month Performance-4.48%9.57%6.72%3.05%1 Year Performance107.35%14.06%30.59%25.05% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics3.127 of 5 stars$1.28-0.8%$4.00+212.5%+118.6%$16.97MN/A-1.204Earnings ReportShort Interest ↓CUECue Biopharma4.5113 of 5 stars$0.83+0.0%$4.00+381.1%+27.4%$62.62M$9.29M-1.2460Earnings ReportGap UpZIVOZIVO Bioscience0.2582 of 5 stars$16.21+11.9%N/A+112.4%$61.87M$15.85K-3.3210News CoverageIZTCInvizyne TechnologiesN/A$9.84-1.7%N/AN/A$61.52MN/A0.0029Gap DownAPLTApplied Therapeutics4.4641 of 5 stars$0.45+5.5%$6.10+1,258.3%-92.0%$60.26M$460K-1.0430News CoverageEarnings ReportShort Interest ↓Gap DownICCCImmuCell0.4072 of 5 stars$6.66flatN/A+90.9%$60.19M$26.49M-95.1370News CoverageEarnings ReportShort Interest ↓IMAImageneBio3.3233 of 5 stars$14.74+0.5%$35.50+140.8%-26.2%$58.97M$9.16M-1.9270VRCAVerrica Pharmaceuticals4.59 of 5 stars$6.70+5.5%$80.00+1,094.0%-80.3%$58.73M$7.57M-0.5640Earnings ReportShort Interest ↓DRRXDURECT1.8512 of 5 stars$1.87flatN/A+42.9%$58.05M$2.03M-12.4780Earnings ReportShort Interest ↓BMEABiomea Fusion3.6559 of 5 stars$1.53-0.6%$16.80+998.0%-69.0%$57.86MN/A-0.5050ANLAdlai Nortye1.3748 of 5 stars$1.61+3.2%$9.00+459.0%-46.7%$57.56M$5M0.00127Short Interest ↑Gap Up Related Companies and Tools Related Companies Cue Biopharma Alternatives ZIVO Bioscience Alternatives Invizyne Technologies Alternatives Applied Therapeutics Alternatives ImmuCell Alternatives ImageneBio Alternatives Verrica Pharmaceuticals Alternatives DURECT Alternatives Biomea Fusion Alternatives Adlai Nortye Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOTH) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access